U.S. approves Spectrum Pharma’s purchase of Allos
WASHINGTON (Reuters) – U.S. antitrust officials have approved Spectrum Pharmaceuticals’ purchase of cancer drugmaker Allos Therapeutics, a $206 million deal aimed at giving Spectrum access to the Allos anti-cancer drug Folotyn. The Federal Trade Commission posted letters on its web site sent to lawyers for Allos and Spectrum dated August 28 which said it had been investigating the deal but had closed the probe, indicating that the transaction could go forward. Henderson, Nevada-based Spectrum agreed in April to buy Allos for about $1. …